Dicerna Pharmaceuticals (NASDAQ:DRNA) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.
Profitability
This table compares Dicerna Pharmaceuticals and Calliditas Therapeutics AB (publ)'s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Dicerna Pharmaceuticals | -88.81% | -71.72% | -16.60% |
| Calliditas Therapeutics AB (publ) | N/A | -26.80% | -25.38% |
Valuation & Earnings
This table compares Dicerna Pharmaceuticals and Calliditas Therapeutics AB (publ)'s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Dicerna Pharmaceuticals | $23.90 million | 93.02 | $-120,460,000.00 | ($1.76) | -16.55 |
| Calliditas Therapeutics AB (publ) | $19.56 million | 34.44 | $-3,450,000.00 | ($0.19) | -142.00 |
Calliditas Therapeutics AB (publ) has lower revenue, but higher earnings than Dicerna Pharmaceuticals. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Dicerna Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Dicerna Pharmaceuticals and Calliditas Therapeutics AB (publ), as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Dicerna Pharmaceuticals | 0 | 0 | 7 | 0 | 3.00 |
| Calliditas Therapeutics AB (publ) | 0 | 0 | 5 | 0 | 3.00 |
Dicerna Pharmaceuticals presently has a consensus price target of $40.4444, indicating a potential upside of 38.51%. Calliditas Therapeutics AB (publ) has a consensus price target of $40.80, indicating a potential upside of 51.22%. Given Calliditas Therapeutics AB (publ)'s higher probable upside, analysts clearly believe Calliditas Therapeutics AB (publ) is more favorable than Dicerna Pharmaceuticals.
Institutional & Insider Ownership
80.6% of Dicerna Pharmaceuticals shares are held by institutional investors. Comparatively, 11.9% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 11.3% of Dicerna Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Dicerna Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 7 of the 12 factors compared between the two stocks.
